in labor induction
Unique combination of efficacy, safety and patient satisfaction
Multiple mode of action\textsuperscript{1} mimics physiological processes of the labor

- Mechanical: Controlled pressure on the cervical wall dilates the cervix
- Biophysical: Partial reversible osmotic dehydration softens the tissue
- Physiological: Promotion of endogenous prostaglandins release causing collagen degradation and tissue restructuring

\textbf{Dilapan-S\textsuperscript{®} doesn’t contain any pharmacologically active substance, which could be released during its use.}

Recommended treatment protocol:

3–5 rods of Dilapan-S\textsuperscript{®} for 12 hrs (overnight)*

12 hours (maximum insertion time is 24 hrs)

\begin{itemize}
  \item YES
  \begin{itemize}
    \item Artificial rupture of membranes**
  \end{itemize}
  \item NO
  \begin{itemize}
    \item New series of Dilapan-S\textsuperscript{®} rods or another ripening agent
  \end{itemize}
\end{itemize}

\textbf{SUCCESSFUL CERVICAL RIPENING}

\textbf{1–2 hrs waiting for onset of uterine contraction}

\textbf{UTEROTONICS***}

\textsuperscript{* Number of pieces can differ depends on initial Bishop score.
** Artificial rupture of membranes (ARM) can be proceeded if beneficial and in line with local clinical protocol.
***Usage of uterotonics, such as oxytocin, is recommended to promote adequate uterine contractions in case that ARM does not lead into onset of spontaneous vaginal labor.
Dilapan-S®

Unique combination of efficacy, safety and patient satisfaction

**Efficacy**
- Significant Bishop score increase \(^2\text{-}^{11}\) and vaginal delivery rate up to 80% \(^2,3,4\)
- Cervical ripening achieved in 94.4% \(^2\)
- Suitable for VBAC \(^2,3,6,10\)

**Safety\(^2\text{-}^{11}\)**
- No hyperstimulation or fetal pathology during cervical ripening
- No infectious complications related to the use of Dilapan-S®
- Practically no limitations related to mother’s gestational age and/or comorbidities

**Patient satisfaction**
- Low rate of uterine contractions during cervical ripening \(^2,3,5\text{-}^{8},10,11\)
- Up to 90% of women can relax or sleep during cervical ripening \(^5\text{-}^8\)
- Minimising of vaginal examination during cervical ripening

**Cost-effectiveness**
- Saving time of health care professionals thanks to one-time application and no need of continuous CTG monitoring \(^12\)
- Out-patient regimen (home cervical ripening) for low-risk groups of patients \(^2,9,10\)
- Potential prevention of C. sections in high-risk groups of patients \(^3\text{-}^9\)

- **For clinicians** – helps to minimise safety risks while maintaining high efficiency \(^2\text{-}^{11}\)
- **For mothers** – ensures gentle and predictable cervical ripening and promotes natural vaginal delivery \(^2\text{-}^{11}\)
- **For health care providers** – offers reduction of overall healthcare cost \(^2,3,4\)

* VBAC — vaginal birth after Caesarean
• Fast acting hygroscopic cervical dilator made of patented AQUACRYL hydrogel specifically developed for obstetrics and gynaecology.¹

• Approved in more than 40 countries worldwide² for labor induction, including USA [510(k), Class II] and EU [CE mark, Class IIa].

• Manufactured at an ISO 13485 certified facility. Sterilized by gamma irradiation.

Sources/References:
1. Druneccky T et al.: Experimental comparison of properties of natural and synthetic osmotic dilators. Arch Gynecol Obstet. Published online: 25 January 2015
7. Zahnemsky J et al.: The impact of the number of pieces of osmotic dilator Dilapan-S® used for cervical ripening on the course and outcome of labor. Poster presentation. 13th World Congress in Fetal Medicine, June-July 2014, Nice, France
8. Vlk R et al: Efficacy and safety of the osmotic dilator Dilapan-S® for cervical ripening in women with/without C. section. Poster presentation. 13th World Congress in Fetal Medicine, June-July 2014, Nice, France
9. Simetka O et al.: Effect of hygroscopic dilator (Dilapan-S®) on cervical ripening prior to induction of labor. Poster presentation. XXIV. European Congress of Perinatal Medicine, June 104, Florence, Italy
12. Data on file
13. Dilapan-S® Instruction for use

¹ The date of January 2016 it is 44 countries. Worldwide registrations including premarket notifications, no objection letters and other types of governmental approvals and EEA incl. Switzerland and Turkey.